{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-095450","form_type":"8-K","ticker":"CALC","cik":"0001534133","company_name":"CalciMedica, Inc.","filed_at":"2024-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.424106+00:00","generated_at":"2026-05-31T10:01:49.036518+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"CalciMedica reports Q2 net loss $4.0M; cash $19.1M; positive CARPO topline data","bullets":["Q2 2024 net loss $4.0M ($0.36/share) vs $3.8M for six months; operating loss $6.5M in Q2.","Cash, equivalents and short-term investments $19.1M as of June 30, 2024; runway into H2 2025.","Phase 2b CARPO trial for Auxora in acute pancreatitis met primary objective with statistically significant dose response.","First patient dosed in Phase 2 KOURAGE trial for severe AKI; topline data expected in 2025.","Company added to Russell Microcap Index effective July 1, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-095450","json":"https://secwatch.observer/filing/0000950170-24-095450.json","markdown":"https://secwatch.observer/filing/0000950170-24-095450.md","text":"https://secwatch.observer/filing/0000950170-24-095450.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534133/000095017024095450/0000950170-24-095450-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534133/000095017024095450/ck0001534133-20240812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:01:49.036518+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}